M, trading at $0.12 on the NASDAQ. This SniperIQ fundamentals page covers Liminatus Pharma, Inc. Class A Common Stock's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
M
Net Margin0.0%

Full research coverage

Frequently Asked Questions

What is Liminatus Pharma, Inc. Class A Common Stock's market cap?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a market capitalization of approximately

M, trading at $0.12 on the NASDAQ. Market cap moves with the live share price.

How profitable is Liminatus Pharma, Inc. Class A Common Stock?

Liminatus Pharma, Inc. Class A Common Stock runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Liminatus Pharma, Inc. Class A Common Stock pay a dividend?

Liminatus Pharma, Inc. Class A Common Stock does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Liminatus Pharma, Inc. Class A Common Stock financially healthy?

Liminatus Pharma, Inc. Class A Common Stock carries a debt-to-equity ratio of -10.88x and a current ratio of 0.96x, with a market beta of 0.74. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Liminatus Pharma, Inc. Class A Common Stock a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Liminatus Pharma, Inc. Class A Common Stock (LIMN) the key facts are: market cap

M, 52-week range 0.095-9.38. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Liminatus Pharma, Inc. Class A Common Stock's full fundamentals live

Get Liminatus Pharma, Inc. Class A Common Stock's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.